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Tuberculosis (TB) remains a major threat to human population as currently 
Mycobacterium tuberculosis (MTB) infects nearly 33% of the global population. 
Annually, about one and a half million deaths are caused by tuberculosis (TB). 
Current reports suggest that approximately nine million new TB cases are 
reported every year. There is an available therapy for TB, however it is quite 
lengthily and consists of numerous antibiotics leading to treatment dropout. This 
treatment incompletion has been linked to the major cause for the appearance of 
drug-resistant species of MTB. Consequently, alternate therapies to treat TB are 
needed. Bacillus Calmette-Guerin (BCG) remains the only vaccine of choice 
since its inception in 1921. Although BCG mounts host protective T helper1 
(Th1) cell activation, which plays a pivotal role in host protection against TB, its 
efficacy is inadequate, suggesting that additional methods to enhance protective 
immune responses are needed. We have also shown that simultaneous inhibition 
of Th2 cells and Tregs by using pharmacological inhibitors (suplatasttosylate and 
D4476, respectively) dramatically enhance MTB clearance and induces a superior 
Th1 response. Here we show that treatment with these two immuno-modulators 
during BCG vaccination dramatically improves vaccine efficacy. Furthermore, we 
demonstrate that these drugs induce a shift in T cell memory development, 
towards central memory T (Tcm) cell responses. Collectively, our findings 
provide evidence that concurrent inhibition of T helper cells type 2 and Tregs 
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 Tuberculosis (TB) places a massive burden on global public health. Every year 
nearly nine million new TB cases appear and it causes approximately one and a 
half million deaths annually (WHO, 2012). MTB is mainly transmitted via the 
respiratory route and nearly 5-10 % of the individuals develop active tuberculosis 
after MTB infection. The host immunity is a key determinant of outcome to 
infection and disease. Current studies on TB patients and mice models have 
demonstrated the fundamental roles of CD8+ and CD4+T cells in clearing MTB 
(Chensue, S et al, 1994). However, HIV-infected individuals are reported to 
extremely susceptible to acquisition of new MTB infection along with 
reactivation of latent infection (Barnes et al 1991, Snider, D. E., Jr. et al 1992). 
Altogether, these reports have taken us to the conclusion that the CD4+ T helper 
(Th1) cells play a decisive role in combating pulmonary TB. MTB overcomes 
host immunity by modulating the equilibrium of Th cell. Th1 cells play vital role 
in host protection from MTB infection. Consequently, individuals with alterations 
in their Th1 responses remain exceedingly susceptible to MTB infection (Flynn, J. 
L et al 2001, Lienhardtet al 2002). Nevertheless, activation of Th1 cell alone is 
not adequate to confer protection against MTB (Aggeret al 2001, Demissieet al 
2004). Activation of Th2 cells promotes TB disease development by antagonizing 
Th1-type immune responses (Lienhardt, C. et al 2002). IL-4 cytokine expression 
has been observed in human granulomas (Fenhalls, G et al 2000) and correlate 
with the immunopathology of tuberculosis (Ordway, D. J et al 2005, Seah, G. T et 




vaccinated individuals mounted robust Th2 responses and failed to protect them 
from MTB infection (Dlugovitzky, D. et al 1999, Rook et al 2005). In the same 
way, it was observed that mice lacking IL-4 exhibited limited resistance to MTB 
infection (Hernandez-Pando et al 2004, Rook et al 1996). Collectively, this 
suggests that Th2 cells augment host susceptibility to MTB infection. However, 
other investigations further showed that MTB induces the proliferation of MTB 
specific FoxP3-expressing regulatory T cells (Tregs) (Scott-Browne et al 2007) in 
the draining lymph nodes (Shafiani, S et al 2007). These MTB specific Tregs 
cells hamper IFN- production by T cells and inhibit activation of protective 
immunity within the host (Nakamura, K. et al 2001, Randolph, D. A. 2006), 
thereby promoting disease progression.  
 As mentioned previously, the only TB vaccine presently available is the BCG, 
and it is estimated that three billion people have received it to date. BCG does not 
protect against MTB infection, but it has been shown to play a role in preventing 
dissemination of TB meningitis. Its efficacy against adult pulmonary tuberculosis 
was reported to vary greatly between 0-80% in different populations depending 
on the ethnicity and geographical locations (Colditz, G. A et al 1994). Recent 
studies have indicated that BCG vaccinated animals mainly developed antigen-
specific CD4+ cells effector memory (Tem) cells. This failure of BCG to induce 
central memory cells (Tcm), may be the reason for its poor efficacy (Henao-
Tamayo, M. I. 2011).  
 It is well documented that MTB survives, replicates and multiplies unhindered by 




that T cell activity is indispensable for anti-tuberculosis immunity. Previous 
studies suggest that, those  that resist TB disease manifestation, mount 
tuberculosis antigen specific Th1 responses, as determined by the production of 
IFN-, lymphotoxin (LT) and tumour necrosis factor-alpha (TNF-) (Goldsack, 
L et al 2007). Similarly, individuals with faulty genes for the production of IFN- 
or IFN- receptors are highly vulnerable to TB disease manifestation (Ottenhoff, 
T. H 1998). Recent reports support the well-established fact that, Th1 cells 
generated against MTB are indispensable for the expulsion of harbored tubercle 
bacilli from the host (Flynn, J. L.et al 1993). However, several studies indicated 
that only Th1 response is inadequate for the protection against TB (Bhattacharyya 
et al 1999). On the other hand, TB disease susceptible animals mount progressive 
Th2 responses, predominated by production of IL-4, IL-5 and IL-13 (Rook et al 
2007). Thus, elevation of Th2 responses might be responsible for enhanced 
susceptibility to TB disease. This hypothesis was strengthened by the fact that IL-
4 deficient mice show resistance to MTB infection (North R. J., 2007). Similarly, 
studies assessing the expression of cytokines in TB granulomas in patients with 
advanced TB, detected an enhanced IL-4 production (Fenhalls, G et al 2000). 
Interestingly, elevated Th2 responses has been noted in the patients who were not 
protected by BCG (Dlugovitzky D et al 1999). Based on the above-mentioned 
points, it is clear that Th2 cells alone are not the only factor contributing to host 
susceptibility to TB. Another T cell subset recently described, Treg cells,  are 
phenotypically distinct, CD4+CD25+FoxP3+ T Cells and have been discovered to 




(Allan, S. E. et al 2008). It has been documented that TB induces a state of 
immuno-suppression in susceptible hosts. The progression of tuberculosis disease 
has been linked to the expansion of Treg cells (Scott-Browne, J. P.  et al 2007). 
Antigen specific Treg cells increased within three weeks of infection, creating a 
conducive environment for proliferation of bacterial cells (Shafiani, S. et al 2011), 
and inhibiting effective Th1 responses. Cytokine requirements for the 
differentiation of Treg cells remain unclear. However, it has been established that 
FoxP3 transcription factor is necessary, which is induced by TGF-signalling. 
Literature also suggest that combined inhibition of Th2 responses and Tregs are 
necessary for protective immune responses in the host and generation of Th1 cells 
responses is obligatory and adequate for controlling TB disease (Sweeney, K. A. 
et al 2011).  
Thus, it is conceivable that mounting Th1 responses along with simultaneous 
inhibition of Th2 and Treg responses may be the answer to effective resistance 
against TB. To address this, we attempted to enhance the host protective immune 
response against MTB by inhibiting Th2 and Treg cells through small molecule 
inhibitors with BCG. Here, we simultaneously used both Th2 and Treg inhibitors 
to enhance the efficacy of BCG vaccination which generated higher Th1 
responses. Furthermore, we observed a dramatic switch of Tem to Tcm. As Tcm 
plays the central role in host protection and determines vaccine efficacy, animals 
treated with these two inhibitors exhibited significantly improved vaccine efficacy 
when used along with BCG. Therefore, this strategy needs to be further evaluated 




2. REVIEW OF LITERATURE                                                                                                                                                                                                                                                           
2.1 Tuberculosis: The Global Epidemic 
TB annually cause nearly 1.7 million deaths (WHO, 2012) and is the  second 
leading cause of mortality from any single infectious disease globally, after 
HIV/AIDS (Corbett et al 2003). Nearly 33% of the total world population carry 
latent MTB infection (WHO, 2004). On an average approximately 10 percent of 
MTB infected individuals develop active TB disease (Bloom and Small, 1998), 
and this percentage dramatically increases in the event of HIV infection (Selwyn 
et al., 1989;Girardi et al., 2000). HIV immunosuppression fuels the TB epidemic 











Figure 1 Estimated TB incidence rates, 2012 (Adapted from WHO Report 




On an average, out of ten immuno-competent individuals infected with MTB, one 
can develop active TB in his whole life, but in co-infection with HIV, this rate is 
one out of ten in just a single year. In tuberculin test positive AIDS patients, one 
in two or three has a chance of mounting active TB disease (Corbett et al 2003). 
In industrialized countries, HIV makes up only a small number of  TB cases but in 
developing countries, this situation is worst and remains as serious concern. 
The worldwide spread of TB is generally associated with economic settings, 
maintaining its tightest grip on the populations of poor and under developed 
continents such as  Africa, Asia, and Latin America (Frieden et al 2003; Corbett 
et al 2003). The rate of TB incidence largely ranges from >25/100,000 in North 
America to > 299/100,000 in western Russia and Asia to ~300/100,000 in Central 
and Southern Africa (Figure 1) (WHO, 2012). Furthermore, 95% of new TB 
cases and 99 % of deaths due to TB occur primarily in low income countries 
(Dye, 2006). Prior to the mid-1980s, a steady drop in TB cases was observed in 
developed countries, which then subsequently, began to see an increase in recent 
times. The re-emergence of TB is a severe global public health threat and this 
became more complex with the emergence of Drug-Resistant TB like MDR, XDR 










2.2.1 Historical Perspective 
Mycobacterium genus was originated nearly 150 million years ago (Daniel, 2006). 
Presumably around 3 million years ago, MTB predecessor co-evolved with early 
hominids in East Africa. Reports suggests that nearly 15,000 - 35,000 years ago 
the more recent members of MTB complex were originated from a common 
progenitor (Gutierrez et al., 2005). The presence of MTB has been documented in 
the prehistoric humans remnants (4000 BC) and in Egyptian mummies  (3000-
2400 BC) (Zink et al 2003). In earlier times TB was known as “phthisis” - a 
Greek term that means ‘consumption’ indicating extensive weight loss due this 
disease. It was Hippocrates who first identified tuberculosis as a fatal disease 
around 460 BC and named it phthisis. J.L. Schoenlein gave the disease its present 
name “tuberculosis” in 1839. 
MTB, the bacillus causing TB was first described in 1882 by Robert Koch. Albert 
Calmette and Camille Guerin introduced Mycobacterium bovis BCG vaccine in 
1921, which remains the only vaccine against TB to date; however BCG efficacy 
against adult pulmonary TB remains questionable. In 1946, the antibiotic 
streptomycin was utilized as a treatment drug for TB (MRC, 1948). 
Notwithstanding, such advancements in the field of TB treatment, in 1980s and 
early 1990s multi-drug resistant tuberculosis (MDR-TB) and extensively-drug 
resistant tuberculosis (XDR TB) causing MTB strains emerged as a serious threat 
to TB control and management (CDC, 1990; CDC, 1993; CDC, 2007; Crawford, 





















Major characteristics of Mycobacterium tuberculosis complex organisms are:  
 
 MTB is an obligate aerobe and grows most efficiently in the lungs 
 It is a facultative intracellular pathogen and typically infects mononuclear 
phagocytes such as monocytes, macrophages or dendritic cells 
Superkingdom : Bacteria 
Phylum : Actinobacteria 
Class : Actinobacteria 
Subclass : Actinobacteridae 
Order : Actinomycetales 
Suborder : Corynebacterineae 
Family : Mycobacteriaceae 
Genus : Mycobacterium 
Species group : Mycobacterium tuberculosis  
complex 




 It grows very slowly (generation time is 12 to 18 hours) compared to other 
bacteria (for example, the generation time of Escherichia coli is only about 20-30 
minutes) 
 Its cell wall is rich in lipids and extremely hydrophobic in nature. Therefore they 
are impervious to most of the regular stains like Gram’s stain 
 Due to the presence of lipid-rich cell walls, these bacteria are comparatively 
impervious to a variety of basic dyes unless they are pooled with phenol. The 
stained MTB resists de-colorization from acidified organic solvents, hence called 
“acid-fast” bacilli.  
2.2.3 Morphology of MTB 
MTB bacteria appear as long thin rods, usually straight or slightly curved (Figure 
2) that frequently show irregular beading due to vacuoles and polyphosphate 
granules. The bacillus is 1-10m (usually 3-5m) long and 0.2-0.6m wide. This 
is a non-motile, non-spore forming and non-capsule forming bacterium. The lipid 
content in this bacteria is high, possibly the highest among all other bacteria. This 
waxy coat confers the acid fastness, extreme hydrophobicity, and little 
permeability to many known antibiotics (Chambers et al., 1995; Bhatt et al 2007; 
Glickman and Jacobs, 2001). In the envelope structure, Mycobacteria contain 
mycolic acids and complex long-chain fatty acids that are found only in Nocardia 
and Coryne bacterium. Owing to the presence of N-glycolyl muramic acid in the 




fast bacterium. This characteristic is of a great practical importance since it is 
used to identify Mycobacteria in pathological specimens. 
 
Figure 2. Scanning Electron Micrograph of Mycobacterium tuberculosis 
(Image courtesy-Dr. Ray Butlar / CDC) 
 
2.3 Pathogenesis 
This tubercle bacillus mainly infects hosts via the respiratory tract. The inhaled 
bacteria proceed towards distal sites in lungs and establish infection (Gupta and 
Chatterjee, 2005). MTB preferably infects lungs although it has capacity to infect 
in other tissues as well. Extra pulmonary TB develops in 10 to 25 percent of all 
the reported cases (Bloom and Small, 1998; Golden and Vikram, 2005; Mehta et 
al 1991; Yoon et al 2004). Patients suffering from TB expel MTB bacilli in the 
form of droplets while coughing and sneezing. Alveolar macrophages engulf 




mount MTB specific T cells immune response and form granuloma in lungs to 
contain MTB on site of infection (Shoenfeld and Rose, 2005). MTB has the 
ability to replicate within the macrophages (Algood et al 2003; Algood et al  
2005; Flynn and Chan, 2005; Ulrichs and Kaufmann, 2006). Macrophages and 
lymphocytes migrate to the site of infection and form a granuloma (Gonzalez-
Juarrero et al 2001). Besides concentrating the immune response directly at the 
site of MTB infection, the other function of the granuloma is to avoid spread of 
MTB to other parts of the lung as well as different organs. The granuloma can 
develop into tuberculous lesions, most likely due to chronic stimulation of the 
immune cells at the site of infection (Flynn and Chan, 2001). Live bacilli have 
been isolated from the granulomas of patients with clinically inactive 
tuberculosis, which suggest that MTB can persist for long periods within the 
granulomatous lesions (Opie and Aronson., 1928; Robertson, 1933). Calcification 
in granuloma is observed if MTB infection is effectively contained at the site of 
its infection (Doherty and Andersen, 2005). However, granulomas enlarge in size 
and cellularity, if host immune response is not able to effectively control MTB 
replication. Ultimately, necrosis and cell death take place at hypoxic centre of the 
granuloma. In individuals with active TB disease, bacteria replicate and develop 
cavitary lesions. Subsequently, granuloma becomes caseousas a result of cellular 
degeneration and devastation (Dannenberg, 1993). During TB disease progression 
lipid rich material acts as a nutrient supply for the growth of MTB. Finally, 
dissemination of MTB takes place because of subsequent destruction and 




as a result of lung tissue destruction and necrosis which ultimately develops into 
classical TB symptoms like blood in sputum and persistent cough (Abebe et al 
2010; Doherty and Andersen, 2005). During this phase, patient is infectious and 
able to spread MTB via aerosol to healthy individuals. Patient with active TB 
disease can spread this disease and according to reports, can perpetuate this 
infection to about 10-15 people (Kaufmann, 2000).  
Nearly 10 percent of the MTB infected people in their lifetimes will develop 
clinically active TB (Bloom and Small, 1998), but it becomes fatal if the disease 
is established and remain untreated (Tiemersma et al 2011). Disease outbreak is 
delayed because the progress of infection is very slow. In the adult, tuberculosis 
occurs most commonly as a result of the reactivation of the existing foci, rather 




A granuloma is a mass of immune cells, comprised of a core of activated 
macrophages, enclosed by activated lymphocyte, which is formed to restrict or 
contain the foreign substance or pathogen that cannot be eliminated. The center of 
the granuloma often contains multinucleated giant cells, langhans cells,  formed 
by the fusion of activated macrophages (Pritchard et al 2003; Lay et al 2007; 
Murphy et al 2008). These extremely large cells are generally enclosed by large 
modified macrophages which look like epithelial cells and referred to as 





The granuloma is the result of a vigorous cellular immune reaction to MTB 
components. The inhaled bacteria are internalized by alveolar macrophages and 
encouraged to infect the lung epithelium cells (Algood et al 2005; Flynn and 
Chan, 2005; Ulrichs and Kaufmann, 2006). The production of inflammatory 
chemokines and TNF-α by MTB infected macrophages results in the recruitment 
of different immune cells like natural killer NK T cells, neutrophils, CD8+ and 
CD4+ T cells, which subsequently amplify the cellular localization and 
remodeling of the MTB infection site (Algood et al 2003). Altogether, this 
inflammatory response is synchronized and superseded by the production of 
interferon IFN-γ. Subsequently, granuloma becomes stable, identifiable and 
emergence of the stratification takes place (Kaplan et al 2003; Ulrichs et al  
2005). Furthermore neo-vascularization is observed in mature-phase granulomas 
(Kaplan et al  2003; Dheda et al  2005a; Ulrichs and Kaufmann, 2006).  
In presence of a strong immune response, latent infection results in asymptomatic 
and non-transmissible state and finally granulomas may be reduced to small 
fibrous and calcified lesions (Doherty and Andersen, 2005). On the contrary, 
suppression of the immune status of host, the granuloma casemates, rips apart and 
leaks viable and infectious MTB into the airways, leading to the spread of 
infectious MTB bacilli (Figure 3). 
The formation of granuloma has long been considered to be a necessary 
mechanism for the MTB containment, however a recent study suggested that 




finding indicates that granuloma formation cannot only be considered as an 
important process for host protective immunity against TB, but also leads to the 
establishment of latent TB infection, which makes it difficult for host immune 
system to resolve and clear MTB. 
 
 
Figure 3. The pathology of granuloma. The granuloma comprises of a core of 
MTB infected macrophages encircled by foamy macrophages and other 




fibrous cuff of collagen and other extracellular matrix components that delineates 
the periphery of the structure. (Adapted from Russel, 2007) 
2.4 Innate immune response to MTB Infection 
MTB infects, survives, and replicates within phagocytes (macrophages, 
monocytes, and immature dendritic cells) of susceptible hosts. These phagocytes 
provide a first line of defense, and in most cases, degrade the microorganisms 
shortly after engulfment. Disintegration of the ingested organisms is initiated after 
phagolysosome fusion. The acidic environment of the lysosomal contents and the 
hydrolases that are present in this compartment, destroy the microorganisms. 
However, MTB counters this host immune defense by several mechanisms such 
as  mycobacterial sulfatides and lysosomotropic polyanionic glycolipids which 
have the ability to inhibit phagolysosome fusion (Goren et al  1976a; Goren et al 
1976b; Middlebrook et al 1959). Furthermore, MTB produces copious amounts of 
ammonia, which effectively neutralizes the acidic environment of the 
phagolysosome, and successfully inhibits phagolysosome maturation (Gordon et 
al  1980).  
Enzymatically, cleaved antigens intersect/interact/interfere with the cellular 
antigen processing machinery and are eventually presented on the cell surface via 
Major Histocompatibility Complex (MHC) molecules. The antigenic peptides are 
recognized by T cells, which lead to the generation of MTB specific T cell 
responses. In addition to the MHC-bound peptide, optimal activation and 




molecules on the same APCs appropriate cytokines and chemokines, and lipid 
mediators secreted at the inflammatory site. The microenvironment at the 
inflammatory site is predominantly generated by innate immune components 
upon recognition of Pathogen-Associated Molecular Patterns (PAMPs). These 
PAMPs are recognized by Pattern Recognition Receptors (PRRs) expressed by 
innate immune cells. 
MTB produces several PAMPs, including lipoarabinomanan, phenolic 
glycolipids, phosphatidylinositol mannosidase and lipoproteins. These molecular 
patterns are recognized by innate receptors, called TLRs, on macrophages and 
DCs (Brightbill et al 1999). Interestingly, ligation of these PAMPs triggers both 
protective and pathogenic immune responses (Hawn et al 2006). However, it is 
not clear whether the balance by which these receptors are engaged during MTB 
infection contributes to susceptibility and resistance. It has been shown that 
signaling through TLR2 and TLR9 provides the strongest host resistance in TB 
(Bafica et al 2005). A range of microbial products can be recognized by TLR2 
and heterodimered with other TLR like TLR1 or TLR6 (Takeda and Akira, 2005). 
TLR2 binds early secreted antigenic target protein 6 (ESAT-6) of MTB (Pathak et 
al 2007) which results in extensive modulation of host immune response. TLR2/1 
recognizes mycobaterial phosphatidylinositol mannosidase and other lipoprotein, 
leading to pro-inflammatory cytokines production (Brightbill et al., 1999; 
Underhill et al 1999; Hawn et al 2006). On the contrary, recognition of 
lipoarabinomannan by TLR2 induces production of IL-10, which acts as an 




Unmethylated CpG motifs are recognized by TLR9 which results in the secretion 
of pro-inflammatory cytokines (Hemmi et al  2000). There are two types of CpGs, 
namely A/D-type and B/K-type CpG, both of which are recognized by TLR9 
(Hemmi et al 2003). B/K-type CpG interaction leads to secretion of pro 
inflammatory cytokines like IL, which IL-12 and TNF-which facilitate Th1 
responses (Takeda and Akira, 2005). Whereas, A/D-type CpG triggers interferon 
(IFN-γ)- (a type-I IFN) production by plasmacytoid DCs (Krug et al 2001; 
Verthelyi et al  2001). It has been shown that infection of macrophages by MTB 
induces production of type-I IFNs. Type-I IFNs also assist in mounting Th1 
responses. Although some reports have showed the involvement of TLR-4 in 
mounting inflammatory responses, the role of this TLR in tuberculosis infections 
remains controversial. Upon recognition of ligands, TLRs form dimers, which 
then recruit the TIR domain-containing adapter molecule MyD88, this, in turn 
activates its downstream signals (Takeda and Akira, 2005) except for TLR3, all 
TLRs signal through MyD88. For instance, TLR3 and TLR4 activation signaling 
pathways induces type-I IFN, in contrast activation of TLR5 and TLR2 pathways 
does not induce this cytokine (Takeda and Akira, 2005). However, it is clear that 
the MyD88 pathway is essential for production of immune stimulatory and 
immune inhibitory cytokines as well as accessory molecules by APCs. MyD88-
deficient mice are shown to be susceptible towards infection against MTB in 






2.5 Dendritic Cells and MTB 
Dendritic cells (DC) are the most effective APCs and play a vital role in initiating 
immune responses in naïve animals (Steinman, 1991; Banchereau and Steinman, 
1998). Current lines of research advocate that both myeloid and lymphoid 
precursors may lead to the generation of DCs. DCs are regarded as most potent 
APC because they have a unique ability to find antigen using numerous routes  
via macropinocytosis, clathrin-coated mediated endocytosis or phagocytosis 
which depends upon DC cell maturation state. Additionally, these cells express 
high levels of co-stimulatory molecules like CD80, CD86 and CD40 and MHCII 
which armor these cells to become the potent APCs (Banchereau and Steinman, 
1998). 
Interaction of MTB with DCs has been reported in number of studies. For 
instance, it has been shown that the MTB infection in DCs cause their activation 
(Henderson et al., 1997). Additionally, it has been reported that DCs infected with 
MTB produce increased levels of IL-12, IL-1 and TNF-as inflammatory 
cytokines. Furthermore, it has been established that MTB could multiply in 
murine bone marrow derived dendritic cells (Bodnar et al  2001). Activation and 
maturation of DCs can be induced by MTB lipo-peptides and proteins (Hertz et al 
2001). In addition, CD40 mediated stimulation of MTB infected DCs has 
enhanced potential to mount effective T cell responses by increasing MHC and 
other co-stimulatory molecules expression on DC cell surface (Demangel et al 




model of MTB (Demangel et al 1999). These reports suggest that DCs are 
important in mounting and priming immune responses against MTB. 
2.6 The Th1/Th2 Paradigm in TB 
As mentioned previously, in the pre-AIDS era, approximately 10% MTB infected 
individuals, developed TB in their lifetime (Bloom and Small, 1998). The host 
had therefore evolved the resistance mechanism for controlling tuberculosis. 
Studies from patients and animal models indicate that T cells are an intrinsic part 
of anti-tuberculosis immunity. Historically, it is well-known that CD4+T cells 
play the central function in the resistance to MTB infection (Caruso et al 1999; 
Mogues et al 2001; Scanga et al 2000). However, recently the role of CD8+ T 
cells in TB disease has been underscored. TB resistant individuals usually mount 
MTB antigen-specific Th1 responses, as determined by the production of 
IFNlymphotoxin (LT), and TNF by these cells (Kutlu et al  2007; Salgame, 
2005). In contrast, susceptible animals mount progressive Th2 responses, 
predominated by the production of IL-5, IL-4 and IL-13 (Kutlu et al  2007; Rook, 
2007; Rook et al  2004). Animal models of tuberculosis have confirmed that MTB 
specific Th1 cells are indispensable for expulsion of the harbored tubercule 
organisms (Flynn et al 1993; Cooper et al 1993). Similarly, individuals 
malfunctioning in the IFN-or the IFN- receptor encoding genes are reported to 
be highly susceptible to MTB (Ottenhoff et al 1998). However, several reports 
have indicated that only Th1 cell responses are not adequate for protection against 
TB (Bhattacharyya et al 1999; Elias et al 2005a; Leal et al 2001; Majlessi et al 




PPD, which is the sign of IFN- mediated immune response. Therefore, elevation 
of Th2 responses might be responsible for enhanced susceptibility to TB. This 
hypothesis was strengthened in mice lacking IL-4, which show accelerated 
resistance towards MTB (North, 1998; Saunders et al 2000). Similarly, studies 
investigating the expression of cytokines in human granulomas in advanced TB 
disease have detected an enhanced IL-4 transcription (Fenhalls et al 2000). 
Several other studies have indicated that production of IL-4 and show a 
relationship with the immunopathology and disease progression in animal models 
and patients (Seah et al 2000; Dheda et al  2005b; Ordway et al  2005; van Crevel 
et al  2000). Furthermore, strong Th2 responses have been noted in patients who 
were not protected by BCG (Rook et al 2005; Dlugovitzky et al 1999). 
Nonetheless, it is apparent that Th2 cells are not the only cell type conferring 
disease susceptibility. Thus, it is very likely that promoting Th1 responses and 
simultaneously inhibiting Th2 responses holds the key to effective resistance 
against TB. This hypothesis is strengthened by the fact that latently infected 
individuals, in which MTB is effectively controlled, secretes a great amount of 
IL-4, an endogenous antagonist of  IL-4 generated by alternative splicing from the 
primary IL-4 transcript (Rook, 2007).  
 
2.7 Th17 cells in TB 
The function of T cell responses in TB appears complex. Several other T cell 
subsets have been discovered previously, and the list continues to grow. The 




been studied extensively. Recently Th17 cells have been described as another 
subset of the Th cell lineage. These inflammatory phenotypic cells, are shown as a 
cause for the pathogenesis of several autoimmune disorders, and provide 
resistance to certain bacterial and fungal infections (Jin et al  2008). It appears 
that during MTB infection and TB disease progression, IL-17 does not have a 
defending role (Khader et al 2005; Cruz et al 2006). It has been shown that BCG-
vaccinated IFN--deficient mice develop enhanced numbers of cells producing 
IL-17, but the susceptibility of these animals to BCG remained unaltered (Cruz et 
al 2006). Another study indicated that IL-17 production during primary immune 
response inhibits the generation of an effective secondary immune response 
against TB (Romano et al 2006). In contrast, several other reports have 
established a protective function of IL-17-producing cells for the development of 
MTB specific secondary immune response (Khader et al 2007; Wozniak et al 
2006). Additionally, studies documented that in IFN-deficiency, a strong IL-17-
dependent memory response is produced in BCG-vaccinated animals. This 
memory response successfully protected animals upon subsequent challenge with 
MTB (Wozniak et al  2006). 
Th17 cells differentiation requires simultaneous occurrence of TGF- and IL-6 
(Bettelli et al 2007). MTB infections in macrophages have been shown to produce 
significant amounts of both TGF- and IL-6 (Toossiet al 1995; Van Heyningen et 
al 1997). Thus, it is expected that MTB infections facilitate Th17 differentiation. 
However, it is evident that both Th1 and Th2 subsets inhibit Th17 cells 




Th1/Th2 paradigm in patients and animal models of TB has been well established. 
Furthermore, recent report suggest that for the molecular orchestration of Th17 
differentiation TGF is not essential (Das et al  2009) instead, it strongly inhibits 
differentiation of both Th1 and Th2 cells. Consistent with this idea, IL-6-deficient 
mice showed a marginally increased bacterial burden in the initial phase of 
infection, suggesting a minor protective role of IL-6 confined within the innate 
immune response (Saunders et al 2000). Altogether, it suggests the protective role 
of both Th1 and Th17 cells, in contrast Th2 response have role in the progression 
of  TB disease. 
 
2.8 Treg cells in TB: 
Treg cells are a phenotypically distinct T cell subset, characterized as 
CD4+CD25+FoxP3+ T cells, which play a decisive role in the control of 
autoimmune disorders and other immuno-regulatory mechanisms (Allan, S.E et al 
2008). It is well known that TB induces immunosuppression in susceptible hosts. 
Recent report suggests that regulatory T cells become expanded during TB 
progression, and contribute to disease susceptibility (Scott-Browne, J.P., et al 
2007). However, it is not clear whether these Tregs are natural Tregs or induced 
in the periphery in response to specific MTB antigens (adaptive Tregs). Treg cells 
exert suppressive functions by the production of TGF- (Kretschmer, K., et al 
2006; Lohr, J., et al 2006). Cytokine requirements for the differentiation of Treg 
cells remain unclear. However, it has been established that expression of FoxP3 




2.9 The BCG vaccine – Success, Failures and Reasons  
BCG still remains the choice of vaccine against TB and it closely resembles the 
MTB with approximately 90% DNA homology. BCG was developed by two 
French scientist Albert Calmette and Camille Guerin of Pasteur institute during 
early 20th century using M. Bovis by growing it on culture medium and observing 
its reduced virulence in animals (Calmette and Plotz, 1929). For the first time in 
1921 in France, this newly developed BCG vaccine was used for administration to 
infants, and it was a great success as it was able to significantly reduce infant 
mortality. Since its inception, BCG remains the only choice of TB vaccine 
(Lugosi, 1992). Reports suggests that annually over 0.1 billion doses of BCG are 
administered and in total approximately 3 billion individuals have been 
immunized with BCG (WHO, 2004). Although, BCG vaccine does not confer  
total and permanent immunity, it has been established that BCG induces a certain 
level of protection, mainly in children (Kaufmann, 2000). Large scale studies on 
the efficacy of BCG established that it shows greater protection in children, 
(Colditz et al 1995; Trunz et al 2006) but it has limited efficacy in adults (Fine, 
1995). 
Number of reports suggest that efficacy of BCG in imparting protection against 
TB varies from 0-80% (Colditz et al 1994; Brewer, 2000). In high income 
countries such as UK, North America and Denmark, clinical trials were conducted 
in 1940s and 1950 and it was established that the vaccine is highly efficient, in 
contrast recent trials conducted in Chingleput district of India which showed that 




studies performed in the US showed “negative” efficacy (Bannon, 1999; Fine, 
1995). The reasons behind this variably in protection are largely unknown but 
several hypotheses have been stipulated, which includes genetic or nutritional 
dissimilarity in human populations, exposure of trial populations to environmental 
MTB, differences in trial methods, presence of diversity among the vaccine 
strains used in clinical trials (Behr, 2002; Brandt et al 2002; Comstock, 1994; 
Demangel et al 2005; Fine, 1995; Tsenova et al 2007). Studies using deletion 
analyses of different strains of BCG genome reviled that in several BCG strains, 
there has been loss few important genes required to mount protective immunity 
against TB. Sixteen deletions encoding 129 Open Reading Frames (ORFs) have 
been reported, which encodes a number of key T cell antigens such as the CFP-
10, ESAT-6, CFP-21 and others (Mahairas et al 1996; Weldingh and Andersen, 
1999; Skjot et al 2000). One hypothesis postulated that the absence of such 
immune-dominant antigens in BCG may be the reason why BCG is unable to 
prime a potent MTB protective immune response (Andersen, 2001; Behr et al 
1999; Skjot et al 2000). Support for the significance of these antigenic proteins in 
protection comes from novel vaccine that performs better than BCG, which is 
BCG strain engineered to overproduce ESAT-6 protein (Pym et al 2003). 
It is assumed that some of the important genes of BCG might have been lost 
during attenuation and/or at some stage in propagation (Behr et al 1999). Key 
antigenic proteins either not expressed or absent in a few BCG vaccines, whereas 
they are present in parental strain. However, seeing the experimental 




whether or not these strain variations may account for these ambiguities in 
findings (Oettinger et al 1999). Furthermore, reports have also suggested that, the 
presence of persistent helminth infections can hamper protective anti-TB 
responses induced by BCG. By shifting the host immune response towards a Th2 
type, helminthes can drastically reduce the BCG protective efficacy (Elias et al 
2005b; Malhotra et al 1999). It has been suggested that in developing countries 
failure of BCG vaccine is not due to low Th1 responses but rather because the 
vaccine is rendered ineffective and immuno-pathological in individuals exposed 
to the environmental immunological stimuli abundant in such countries (Rook et 
al 1981). All these details are not equally exclusive; rather all of these may give 
rise to the differences in vaccine efficacy. Besides variable efficacy, there are 
number of other limitations and major drawbacks of BCG. BCG boosters have 
been found to be ineffective (von Reyn and Vuola, 2002), possibly because the 
vaccine strain may not replicate in persons with previous immunization. PPD 
conversion after BCG vaccination has been considered a disadvantage in 
countries where determining MTB infection using the tuberculin skin test is used 
(von Reyn and Vuola, 2002). Severe and life-threatening complications may 
occur, including severe disseminated disease in immune compromised individuals 
including AIDS patients (Quinn, 1989). 
Thus, in view of variable efficacy and various limitations of BCG, development 
of new, efficacious and safe vaccines appears to be the only option left. We 
believe that modification of BCG has the potential to be a future effective 




modulated by H37Rv and the immune response mounted by BCG is a necessary 
first step. 
 
2.10 RD1 region of MTB genome 
A comparative evaluation of the genomes of the virulent MTB: H37Rv and M. 
bovis with M. bovis BCG revealed that many regions were missing in BCG when 
compared to the MTB and M. bovis. These were grouped into what is commonly 
known as Regions of Difference (RDs) (Mahairaset al 1996). It has been reported 
that during long term in vitro propagations of BCG, a large number of mutations 
have taken place and which have resulted in the deletion of many ORFs 
(Andersen, 2001; Behr et al., 1999; Kaufmann, 2001). Furthermore, 129 ORFs 
encoded by 16 deletions have been accounted for in the expression of several vital 
T cell antigens such as CFP-10, ESAT-6, CFP-21 etc (Mahairas et al 1996; 
Weldingh and Andersen, 1999; Skjot et al 2000) and 11 out of 16 deletions were 
exclusive to M. bovis while the other 5 deletions were unique to only BCG. One 
deletion which is designated as RD1, was deleted from BCG strains but present in 
the MTB complex (Harboe et al 1996). RD1 region is a genetic locus encoding 9 
proteins from Rv3871 to Rv3879 (Cole et al 1998). Two open reading frames of 
RD1 region, Rv3874 and Rv3875 encode CFP-10 and ESAT-6 respectively (Cole 
et al 1998) and are co-transcribed (Renshaw et al 2002). 
RD1 region encodes the T-cell antigen ESAT-6, which was originally isolated 
from a highly stimulatory low-molecular-mass fraction of MTB culture filtrate 




ESAT-6 is a possible diagnostic marker for active TB (Ulrichs et al 1998). 
Another MTB antigen CFP10 gene was similarly characterized like ESAT-6, 
which is co-localized in ESAT-6 gene operon (Berthet et al 1998). Using southern 
blotting approach it has been revealed both the esat-6 and cfp10 genes are present 
in MTB, virulent M. bovis and M. africanum, in contrast these two genes were not 
observed in the  BCG vaccine strains as well as in most NTM (nontuberculous 
mycobacteria) (Harboeet al  1996; Skjot et al  2000).  
Though none of the nine open reading frames (ORFs) that comprise RD1 have a 
biochemically assigned function, this region has been carefully scrutinized in 
silico. The predicted functions of several RD1 region genes suggest that they may 
have roles in protein translocation. Further, as CFP-10 and ESAT-6 lack clear 
secretion signals, they may require a novel secretion machinery for export 
(Braunstein and Belisle, 2000), and components of RD1 may form that machinery 
(Cole et al 1998; Gey Van Pittius et al. 2001; Lewis et al 2003; Pallen, 2002; 
Tekaia et al 1999). This hypothesis was proven true when genes (Rv3870, Rv3871 
and Rv3877) were deleted, which ultimately stopped the secretion of ESAT-6 and 
CFP-10. Furthermore, Cox and others also reported that disruption of individual 
RD1-region genes did not put off production of CFP-10 or ESAT-6. Nonetheless, 
an integrated RD1 region was required to secret these proteins (Pym et al 2003; 
Stanley et al  2003; Guinn et al 2004).  
In an experiment when RD1 locus was reintroduced in BCG, it was observed that 
recombinant BCG was more virulent as well as additionally protective compared 




similar to that of MTB was elicited by BCG:RD1, in particular, when BCG:RD1 
was used for vaccination, it was found to induce migration of effector cells to the 
infection sites in lungs of subsequently MTB infected mice more efficiently than 
the mice infected with wild type BCG strain (Majlessi et al 2005).These reports 
imply that RD1 antigens are lost during the attenuation of BCG and can 
comprehensively modulate BCG induced immune response. 
RD1 region seems to be the most important determinant of MTB pathogenesis but 
the mechanism behind this is largely unknown. A number of research studies have 
suggested that the RD1 region modulates early events in MTB infection. Hence, 
RD1 region can be represented as an increasingly relevant genomic region of 
MTB, since it seems to be concurrently involved in better virulence in immuno-
compromised hosts and increased protection in immuno-competent hosts and 
presents a challenge to researchers to identify the tactics employed by MTB to 
ensure its survival in the intracellular environment. 
2.11 The Present Study 
Numerous studies from literature established that Th1 cell responses are 
obligatory to combat TB. It is also known that BCG significantly induces Th1 cell 
response, however, it does not show adequate defense against TB in a lot of 
individuals. In the current study, we found that Stat-6-/-CD4-TGF- RIIDN mice 
which lack the capacity to mount Tregs and Th2 cell response are resistant to 
MTB infection. Moreover, concurrent inhibition of Tregs and Th2 cell subsets 




mice. As these therapeutic agents are not directed to the harbored organisms, they 
should also avoid the risk of promoting the development of drug-resistant MTB. 
We have also shown that simultaneous inhibition of Th2 and Tregs by using 
pharmacological inhibitors D4476 and Suplatasttosylate dramatically enhance 
MTB clearance, and mounts an enhanced Th1 response. Additionally, we 
observed that administration of these two drugs during vaccination dramatically 
improves vaccine efficacy of BCG. Furthermore, we demonstrate that there is a 
shift in effector memory T (Tem) to central memory T (Tcm) cells. As a whole 
we provide evidence that inhibition of Th2 and Treg cells during BCG 












3. RATIONALE OF THE STUDY AND OBJECTIVES 
Currently BCG remains the only available TB vaccine, and it has been globally 
used since its inception in 1921. According to estimations about 3 billion people 
have received it worldwide. But, its efficacy in adult pulmonary tuberculosis is 
below par. Therefore; an effective vaccine is urgently needed. To design an 
effective TB vaccine, it is important to understand why the BCG is not working 
well. During the last two decades it was generally believed that MTB hinders host 
protective Th1 responses, but facilitates Th2 responses to survive within 
susceptible hosts. As these two subsets of Th cells are counter regulatory. Many 
studies were conducted to examine the therapeutic benefit of inhibiting Th2 
responses during MTB infection. Indeed, inhibition of Th2 responses induces 
partial resistance to MTB infection. Thus, in addition to Th2 cells, additional 
immune components also participate in facilitating disease progression during 
tuberculosis. In fact, current reports have recommended that Treg cells play a 
decisive role in facilitating TB disease progression. However, in recent years, the 
members of Th cell family have been increasing at a rapid pace. Therefore, 
immunological parameters induced by BCG and the requirement of immunologic 
responses for optimal vaccine efficacy needs to be re-evaluated. Our first aim will 
be to identify T cell responses, in addition to those induced by BCG, for optimal 
vaccine efficacy. Formerly it has been observed that MTB infected animals that 
were cured with antibiotics show dramatically enhanced host protective immune 




responses induced in these animals have not been evaluated. We have shown that 
mice that are incapable in mounting both Th2 and Tregs cell responses (Stat-6-/-
CD4-TGFβRIIDN) are wholly resistant to MTB infection. On the other hand, 
either the Th2 deficient (Stat-6-/-), or Treg deficient (TGF-RIIDN) only animals 
were partially resistant to MTB infection. Surprisingly, each of these animals in 
T-bet-/- background were dramatically susceptible to MTB infection. These 
observations suggested that combined inhibition of Th2 responses and Treg cells 
has therapeutic benefit, whereas Th1 responses are indispensable for protective 
immune responses in the host. We further validated the data by applying small 
molecule directed immunotherapy using suplatasttosylateand D4476, which 
inhibit Th2 and Treg cells differentiation, respectively.  
Therefore, it is highly likely that inhibition of IL-4 and TGF-signaling will 
improve vaccine efficacy of BGC. Hence, our second aim is to test vaccine 
efficacy of BGC in the presence or absence of suplatasttosylate and/or D4476. 
Furthermore, to unfold the mechanism of such improved vaccine efficacy we will 
determine which subset of T cell is implicated in the enhancement of efficacy of 









4. MATERIALS AND METHODS 
 
4.1 Ethics Statement: 
The guidelines approved by the Institutional Animals Ethics Committee at ICGEB 
(ICGEB/IAEC/IMM-17/2008 and ICGEB/IAEC/IMM-22/2010), New Delhi, 
India were followed for every animal experiment. The in vitro experiments 
conducted in the School of Laboratory Medicine and Medical Sciences, were 
approved by the Biomedical Research Ethics Committee at the UKZN, Durban, 
South Africa (BREC reference No: BCA 274/09) 
 
4.2 Bacterial Infections: 
BCG and MTB H37Rv strains were grown and maintained in 0.02% Tween 80 
containing Middlebrook 7H9 broth (BD Biosciences, Sparks, MD). For the 
determination of the number of viable MTB, oleic acid albumin dextrose catalase 
(OADC) enriched 7H11 agar plates were used. Mice infections were carried out 
via aerosol route. MTB burden in lung, spleen, and liver of mice was determined 
by using nutrient Middlebrook 7H11 agar plates. All MTB experiments were 
carried out in a either BSL II+ or BSL III facility at ICGEB, New Delhi, India and 







BALB/c mice, either Thy1.1+ or Thy1.2+ (Jackson Laboratory, USA) were bred 
and maintained in the ICGEB, New Delhi animal facility. 
 
4.4 Immunization of the mice and treatment with immunomodulators: 
Mice were immunized with BCG subcutaneously (1x106 bacteria) and the 
following day, treated with D4476 (TocrisBiosciences) and suplatasttosylate 
(Tocris Biosciences) at 16 nmol/g of body weight for a total of 10 days and 
subsequently kept in rest for 20 days. Mice were then infected with H37Rv MTB 
via aerosol route and the organs were harvested for determination of bacterial 
burden at consecutive days following infection. 
 
4.5 Drug Treatment: 
H37Rv infected mice were intraperitoneally treated with or without D4476 and/or 
suplatasttosylate (Tocris Biosciences) at 16nmol/g of mice body weight from day 1 
till day 44 after MTB infection. 
 
 4.6 Solutions for Flow Cytometric Analysis: 
Phosphate Buffer Saline (PBS, pH 7.4):13.7 mM sodium chloride (NaCl), 0.27 
mM potassium chloride (KCl), 10 mM Di-Sodium hydrogen phosphate (Na2HPO4) 
and 0.2 mM Sodium di-hydrogen phosphate (NaH2PO4) 




Permeabilization Buffer: 0.1% saponin, 1% Fetal calf serum (FCS) in PBS 
RBC lysis buffer: 0.826 % ammonium chloride (NH4Cl), 0.1 % potassium 
bicarbonate (KHCO3) and 0.0037 % tetra sodium ethylene-diaminetetraacetic acid 
(EDTA) in double distilled water, pH adjusted to 7.2, filtered and autoclaved 
4.7 Cell Staining and Flow Cytometry: 
Intracellular cytokine staining was performed on cells which were first treated with 
PMA (50 ng/ml) and ionomycin (500 ng/ml) in the presence of brefeldin A (10 
μg/ml)(added during last 6 hr of culture) (Sigma-Aldrich or eBiosciences, USA). 
After washing the cells twice, they were permeabilized using Cytofix/Cytoperm kit 
(BD), and stained with the givenantibodies: anti-mouse CD4 (clone GK1.5)-PE-
Cy5, anti-mouse CD4 (clone GK1.5)-APC, anti-mouse CD4 (clone GK1.5)-FITC, 
anti-mouse CD8 (clone 53-6.7)-PE-Cy5,anti-mouse CD4 (clone GK1.5)-PE,anti-
mouse CD62L (clone MPL-14)-APC,anti-mouse FoxP3 (clone FJK-16s)-APC 
(purchased from eBioscience, USA),  anti-mouse CD44 (clone IM7)-PE anti-
mouse CD25 (clone PC61)-APC, anti-mouse IFN-γ (clone XMG1.2)-APC, anti-
mouse IL-4 (clone 11B11)-PE, anti-mouse IL-17A (clone TC11-18H10.1)-PE, 
anti-mouse FoxP3 (clone MF-14)-PE, anti-mouse TNF-α (clone MP6-XT22)-PE, 
anti-mouse IL-6 (clone MP5-20F3)-PE, anti-mouse IL-12 (clone C15.6)-PE, and 
anti-mouse IL-10 (clone JES5-16E3)-PE (purchased from Biolegend, USA). The 
fluorescence intensity was measured by flow cytometry using (FACS CantoIIor 





   
4.8 [3H]-Thymidine incorporation assay of splenocytes: 
Single cell suspensions of mice spleens were prepared by macerating them in 
complete RPMI 1640 (Gibco, Invitrogen, UK). RBC lysis buffer was used to lyse 
RBCs and washed with complete RPMI 1640. Splenocytes were plated in 96-well 
plate at a density of 0.1X106cells/well and stimulated with different 
concentrations of MTB complete soluble antigen (CSA). After 48 hours, these 
cells were pulsed with tritiated thymidine (1.0 Ci per well) (Amersham 
Biosciences UK). Cells were harvested using cell harvester (WallacTrilux) and 
3H-TdR incorporation was measured using a liquid scintillation counter (Perkin 
Elmer, UK). 
4.9   Cytokine assay: 
The spleens of the adoptive transfer mice at 60 days post H37Rv challenge were 
isolated and macerated to single cell suspension and used in the estimation of 
antigen-specific cytokine responses. RBCs lysis was carried out usingTris/NH4Cl. 
After extensive washing, single cell suspensions were plated in 24 well plates at a 
density of 5 × 106 cells/well. These cells were stimulated using CSA of H37Rv 
(50 μg/ml), for 48 hours. The cytokine assay was performed using the culture 








After 60 days of MTB infection, lungs were harvested from mice and processed as 
per guidelines. The dissected lung tissues were fixed in 4% paraformaldehyde and 
processed through alcohol grades, xylene and embedded in paraffin. Following 
paraffin embedding, the tissues were sliced, mounted on slides and dried. After 
drying, the slides were processed by treatment with xylene, alcohol and water. 
Using hematoxylin, slides were stained, rinsed and counter-stained with eosin prior 
to viewing under the microscope.  
 
4.11 T cell adoptive transfer:  
Thy1.1+ mice were gamma-irradiated (8 rads/sec for 100 seconds) and then rested 
for a day. Using lymph nodes of Thy1.2+ background mice, CD4+ T cells were 
isolated and then adoptively transferred into the irradiated recipient mice (2 x 106 
cells per mouse). After 10 days the recipient mice were challenged via aerosol 
route with H37Rv for further experiment. 
 
4.12 Statistical Analysis: 
SPSS10 software was used to carry out statistical analyses. All experiments were 
carried out for three times and significance in data was determined by Tukey’s 
multiple comparison tests and ANOVA (SPSS Software). P value>0.05 was 




For our genetically engineered mice data represent mean +S.D values of four mice 
/group/time point whereas experiments with small molecule-mediated 




















5.  RESULTS 
5.1 Treatment with Th2 and Treg inhibitors increase the efficiency of BCG 
To examine the effect of Th2 and Treg inhibitors on BCG vaccinated mice, 
(Figure 4) we immunized C57BL/6 mice with BCG and concurrently treated them 
with D4476 and suplatasttosylate, for 10 days. These animals were rested for an 
additional 90 days, and re-infected with MTB H37Rv through the aerosol route. 
Organs were harvested and determined the bacterial burden at different time 
intervals (Figure 5A). We observed that co-treatment with these compounds 
drastically enhanced BCG vaccine efficacy, as determined by the significant 
reduction of bacterial loads in various organs (Figure 5A). In order to assess 
changes in the immune responses, we challenged spleen cells isolated from 60 
days post re-infected animals with MTB derived complete soluble antigen (CSA) 
and measured the proliferative response. We noticed that animals that received 
immunomodulators along with BCG, exhibited superior proliferative responses 
(Figure 5B). Histological studies also revealed that animals treated with 
immunomodulators along with BCG shows dramatic reduction of granulomatous 











Figure 4. Schematic diagram of the immunization, treatment and infection of 
BALB/C mice. 




treatment for  
10 days (I.P.) 
Infection with H37Rv via 
aerosol 
Rest for  
20 days 






Figure 5. Curative treatment with immuno-modulators along with single 
BCG immunization reduces bacterial burden significantly. (A) After 
immunization BALB/c mice were treated with suplatasttosylate and/or D4476 at 
16 nmol/g of body weight for a total of 10 days continuously and then kept the 
mice for another 20 days before the aerosol challenge with MTB (H37Rv). 
Bacterial loads (CFU) were measured in lungs and spleens at 60 days post 
infection. Data represent mean ± SD values from two independent experiments of 
four mice/group/time point. (B) Proliferation of spleenocytes in response to CSA 
was measured by [3H]-thymidine incorporation assay. (C) Photomicrographs 




indicated mice, stained with  haematoxylin and eosin. Results shown here are 
representatives of at least three independent experiments. 
 
5.2 Inhibition of Th2 and Treg by suplatasttosylate and D4476 in BCG 
immunized animals significantly enhanced CD4+CD44hiCD62Lhi T cell 
response  
 
To provide insight into the T cell response induced by BCG immunized-
immunomodulators treated MTB re-challenged animals we isolated T 
lymphocytes from spleens of different groups of animals. Phenotypic 
characterization revealed that CD4+ T cells in suplatasttosyle and D4476 treated 
animals were increased significantly than that of BCG alone primed animals 
(Figure 6 A& B). Vaccine efficacy is mostly dependent on the pool of central 
memory cells. BCG primarily induces effector memory cells in lung, and possibly 
that’s why BCG is ineffective. As inhibition of Th2 and Tregs by the use of 
pharmacological inhibitors culminated in a higher resistance to MTB, we 
determined effector memory and central memory cells in immunized animals. 
Phenotypic analysis revealed that approximately half of CD4+ cells are 
CD44hiCD62hi, which is significantly higher than any other group (Figure 7A& 
B). In contrary number of CD44hiCD62lo cells were dramatically decreased as low 







Figure  6. CD4  expression after immunization and treatment of mice. (A & 







Figure 7. Multifunctional  CD4 expression after immunization and treatment 
of mice. (A & B) Expression of different phenotypes (CD44hiCD62Llo, 
CD44hiCD62Lhi, CD44loCD62Lhi) by multifunctional CD4+ T cells. Results are 




5.3 T helper subset responses in immunomodulators-treated BCG 
immunized mice 
To determine whether the treatment with suplatasttosylate and D4476 has an 
effect on the immune responses in BCG immunized animals, we next quantified 
the frequencies of cytokine producing T cells. Our experimental results 
demonstrated that IFN- producing CD4+T cells were dramatically increased 
whereas Th2 cytokine producing cells were decreased in drug treated BCG 
immunized animals, and an opposite trend observed in only BCG immunized 
animals (Figure 8 A& B). Interestingly, we did not detectany changes in Th17 
cytokine producing cells in all groups (Figure 8 A, B&C). Although Th17 
responses help in better vaccine efficacy (Chatterjee, S. et al 2011, Khader, S. A., 
et al 2007) it appears that it’s not absolutely necessary. Treg cells have a 
prominent role in establishing pathogenesis of TB, and hence we wanted to 
establish the status of Treg cells in these animals.  We noticed an abrupt decrease 
of CD4+CD25+FoxP3+ T cells in drug treated BCG-vaccinated animals. We also 
determined other host protective cytokines , that is,  IL-12and IL-6. It was found 
that IL-12, IL-6 and TNF- producing cells were considerably increased in drug 
treated BCG immunized (Figure 9 A& B). We examined IL-10 production in 
these conditions, and found there were no significant difference, which is in 
agreement with previous reports, that IL-10-/- animals are as susceptible as wild 








 Figure 8. BCG immunization and immunomodulators treatment induces Th1 
 phenotype. (A) Intracellular staining for IFN-, IL-4, IL17 from CD4+ T lymphocytes 
 isolated from the spleens of different groups (infected, BCG immunized, BCG 
 immunized and treated) mice. (B) FoxP3 (CD4+ CD25+) of CD4+ T lymphocytes isolated 
 from the spleens of different groups (infected, BCG immunized, BCG immunized and 
 treated) mice. (C) Bar diagram to show the percentage of Intracellular level of cytokines. 
























































Figure 9.  Intracellular  Cytokine Profiling. (A & B) Intracellular cytokine staining for 
 the IL-10, IL-6, IL-12 and TNF production from different groups (infected, BCG 
 immunized, BCG immunized and treated) of mice. Results are representatives of three 


























































5.4 Enhanced central memory T cells protect animals from MTB infection 
To provide further evidence that central memory is generated by treatment with 
immuno-modulators, we immunized Thy1.2 congenic animals and treated the 
animals with suplatasttosylate and D4476. The isolated CD4+ T cells were 
adoptively transferred into irradiated Thy1.1 congenic animals followed by 
infection with H37Rv (Figure 10). Fifteen, thirty and sixty days post infection, 
we measured the bacterial load in mice spleen and lungs, interestingly we 
observed that drug treated mice displayed significantly less bacterial burden than 
untreated mice (Figure 11). This observation pointed out that indeed central 










Figure 10: Diagrammatic sketch of adaptive transfer of CD4+ T cells from 







   
Figure 11. Adoptive transfer of T lymphocytes from BCG immunized and 
treated mice confirm the reduction of bacterial burden. After immunization 
Thy1.1 mice were treated with D4476, and/or suplatasttosylate at 16 nmol/g of 
body weight for a total of 10 days continuously and then kept the mice for another 
20 days then T lymphocytes were isolated from lymph node and injected 
intraperitonialy (5 x 106 cells) to gamma irradiated Thy1.2 before the aerosol 
challenge with low dose of M.tb (H37Rv) (~100 CFU). Bacterial burdens (CFU) 
were measured in lungs and spleens at 15, 30 and 60 days post infection. Data 








5.5 Th2 and Treg inhibitors induce a different distribution of cytokine-
producing CD4+T cell subsets in BCG immunized mice.  
It is well established that pro-inflammatory cytokines IL-6, TNF-, and Th1 
associated cytokines play central role in host protection. Therefore, we measured 
these cytokines in animals that received memory cells and protected from MTB 
infection (Figure 12 A). We observed that IFN- level was much higher in the 
treated mice than untreated, whereas IL-4 level was almost similar (Figure 12 A& 
B). We also determined the T cell polarizing cytokines IL-12, IL-6, TNF- and 
IL-10. Interestingly we observed that IL-12, TNF- and IL-6level were higher in 








Figure 12. Frquency of T cells and cytokine producing cells in post 
adoptively transferred mice. (A) Profile of CD4 and CD8+ T cells count 60 days 
post infection of adoptive transferred mice. (B & C) Intracellular staining for 
IFN- and IL-4 of CD4+ T lymphocytes isolated from the spleens of different 

























































Figure 13: (A & B) Frequency of IL-6, IL-10, IL-12 and TNF- intracellular 
cytokine producing cells of different groups of adoptive transferred mice. 


















































The role of host Th cells balance is well established in MTB infection (Walzl, G., 
et al 2011). In susceptible hosts MTB induces Th2 and Treg cell responses and 
antagonize host protective Th1 cell immune responses. In this study we 
demonstrated that Th1 cells are indispensable for mounting effective immune 
response against MTB, which is in accordance with recently published studies 
(Sweeney, K. A., et al 2011). There is a dynamic balance between Th1 and Th2 
cells and therefore, induction of Th2 decreasesTh1 responses and compromises 
host protection. Indeed, literature suggests that Th2 responses deficient mice are 
moderately resistant towards MTB infection (Rook, G. A., et al 2004). Therefore, 
inhibition of Th1 responses in MTB infected host and induction of Th2 responses 
symbolizes a strategy of MTB to evade host immunity.  
Recently, reports have shown that MTB induces strong Treg cell responses as 
well as facilitates Th2 responses. Treg cells hamper host protective immunity 
(Boussiotis, V. A., et al 2000). Additional studies suggest that Treg cell 
differentiation needs TGF-β and it is secreted by the MTB infected cells as well as 
by infiltrated mesenchymal stem cells (Raghuvanshi, S., et al 2010, Toossi, Z., et 
al 1998, Shafiani, S., et al 2013), our data also provides proof of intense Treg cells 
expansion in MTB infection. One report also suggests that TGF-β is required for 
Tregs cell development, maintenance and expansion. Indeed, previous data also 
pointed out that TGF-β signaling deficient mice are partly resistant towards MTB 
infection (Jayaswal, S., et al 2010). Recent data also suggest that individual 




(Hernandez-Pando, R., et al 2004, Jayaswal, S., et al 2010, Roy, E., et al 2008). 
Consequently, to understand whether or not concurrent suppression of Tregs or 
Th2 cells does have a complementary effect; we created Stat-6-/- CD4-TGF-
βRIIDN mice. We found that these mice demonstrated increased resistance 
towards MTB infection in comparison with the only Stat-6 and only TGF-β 
deficient transgenic strains. Consequently, our data advocate that concurrent 
inhibition of Tregs and Th2 cells may have better therapeutic advantage in 
comparison to the inhibition of only one subset at a time. Nevertheless, the 
possibility of some additional influences by Stat-6 and TGF-β deficiency on MTB 
infection cannot be excluded. It is also worth considering that inhibition of Th2 
and Tregs cells differentiation may also be achieved by using IL-4 and TGF-β 
antibodies. But, these antibodies are quite costly and encompass a few 
disadvantages like antigenicity. We chose to scrutinize small molecule inhibitors 
that could possibly inhibit Tregs and Th2 cells. In this view we found that 
suplatasttosylate has the ability to interrupt IL-4 and other cytokines signaling 
with no effect on IFN-β production (Oda, N., et al 1999). The molecular 
mechanism behind the mode of action of this compound has not been completely 
elucidated, but it has been shown that suplatasttosylate inhibits production of IL-4 
cytokine by directly affecting T cells (Henneekes, H., and Asadullah, K., 2002). 
D4476 works as an ALK5 inhibitor and down regulates Smad3 activation and 





Treatment of mice with MTB infection on currently with these two 
immunomodulators considerably lowered MTB load in diverse organs of mice. 
This immunotherapy failed in mice lacking T-bet, signifying that therapy is 
largely reliant on Th1 cell responses activation. Although the possibility remains 
that these reagents have some direct effect on MTB beside their natural effect on 
Treg and Th2 cell. Nonetheless, our observations reveal that immunotherapy 
using small molecules is effective for TB treatment. The immunomodulatory 
agents used in this study were found not to act directly against harbored MTB; 
therefore this therapy should not discriminate between different drug resistant 
MTB variants. Despite the fact that this therapy against TB treatment is novel, it 
cannot be used for an extended time. It is well acknowledged that TGF-β has an 
indispensable role in host immune homeostasis but dominant negative TGF-β RII 
mice suffered from multi organ inflammation and ultimately death (Kulkarni, A. 
B., et al 1993; Gorelik, L., and Flavell, R. A. 2000). In the similar view, Th2 
inhibition may also results in vulnerability of host toward parasitic infections (van 
der Werf, N., et al 2013). Therefore, we suggest the use of these modulators in 
human TB patients for short treatment periods. It is possible that antibiotics can 
also be used in combination with these immunomodulators which canpotentially 
help in reducing treatment duration and prevents the generation of drug-resistant 
TB strains. Our research revealed that, using small molecule inhibitors; 
concurrent inhibition of Tregs and Th2 cells may have significant potential in TB 




offer very little complications associated with recombinant immunotherapeutic 
agents. 
The Th1 and Th17 cells have important role in host TB protection (Chatterjee, S. 
et al 2011). It is worth highlighting here, that BCG induces sufficient Th1 
responses, however not protective. Therefore, there are two possibilities that 
explain the lack of protection of BCG. Firstly, either BCG does not mount an 
immune response that is critical for optimum host protection, supported by reports 
indicating that BCG is unable to mount Th17 responses, which may play 
additional role in host protection (Chatterjee, S., et al 2011, Wareham, A. S., et al, 
2011, Samuchiwal, S. K., et al 2014). However, in these reports it has been shown 
that mounting additional Th17 responses indeed provides better albeit, incomplete 
protection (Chatterjee, S., et al 2011, Wareham, A. S., et al 2011, Samuchiwal, S. 
K., et al 2014). Secondly, BCG may produce additional immune responses, which 
may hinder host protective immune responses. We have shown that inhibition of 
Th2 and Treg cells by small molecules, significantly enhanced host protective 
immunity. BCG also induces Th2 and Treg cells, and thus may hinder host 
protective Th1 and/or Th17 cells. Our results demonstrated that inhibition of Th2 
and Treg cells by small molecules enhanced BCG induced vaccine efficacy.  Our 
observation that simultaneous inhibition of Th2 and Treg culminates enhanced 
host protective immunity however was not sufficient to completely eradicate 
harbored MTB. Therefore, it appears that a recombinant BCG that can mount both 
Th1 and Th17 responses, and along with inhibition of Th2 and Treg cells is 




Although BCG is not effective in adult pulmonary TB, but its effective in children 
and approximately 4 billion of doses have been administered, a strategy that will 
support booster BCG, that selectively enhances Th1 and Th17 responses is highly 
desired. In this respect, a recombinant BCG along with inhibition of Th2 and 
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Anti-Mouse CD3 Purified 14-0032 e-Biosciences 
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FITC anti-mouse CD4 Antibody 100406 Biolegend 
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